title: The use of granulocyte colony-stimulating factors following peripheral blood progenitor cell rescue after high-dose chemotherapy for advanced breast cancer: a prospective study.
abstract: The use of high-dose chemotherapy followed by hematopoietic rescue is increasing worldwide for solid tumors. Several studies have suggested that the period of absolute neutrophil count (ANC, < 500/ml) may be shortened in patients who receive peripheral blood progenitor cells (PBPC). To estimate the clinical value of granulocyte-colony-stimulating factor, we examined a cohort of 26 consecutive patients with advanced breast cancer who received one or two cycles of high-dose chemotherapy with PBPC rescue with or without filgrastim. Thirty-five courses of high-dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy were administered and evaluated. All patients received PBPC rescue. Sixteen patients (21 courses) received subcutaneous filgrastim (5 mg/kg) following PBPC infusion. Recovery to > or = 500 ANC occurred at a median time of 7 days post PBPC infusion among patients who received filgrastim versus 10 days among patients who received standard support care only (P < 0.01). The administration of filgrastim was not associated with a reduction in the duration of hospitalization, in the total number of days on nonprophylactic antibiotics, number of red blood cell transfusions, time to platelet engraftment, or number of febrile days. This could be the consequence of the high hematopoietic cell dose administered in the study. Therefore, any effect of filgrastim was probably masked by the use of a large number of PBPC. Larger prospective randomized studies, specifically focused on the utility of the administration of growth factors following high-dose chemotherapy and PBPC rescue, may be warranted to know whether the administration of filgrastim after PBPC transplantation is really necessary.
authors.affiliation: Divisione di Oncologia Medica, Ospedale Santa Maria delle Croci, Ravenna, Italy. c.dazzi@ra.nettuno.it
authors.forename: C
authors.initials: C
authors.lastname: Dazzi
authors.forename: L
authors.initials: L
authors.lastname: Albertazzi
authors.forename: G
authors.initials: G
authors.lastname: Rosti
authors.forename: A
authors.initials: A
authors.lastname: Maestri
authors.forename: G
authors.initials: G
authors.lastname: Fiorentini
authors.forename: M
authors.initials: M
authors.lastname: Leoni
authors.forename: A
authors.initials: A
authors.lastname: Tienghi
authors.forename: D
authors.initials: D
authors.lastname: Turci
authors.forename: P
authors.initials: P
authors.lastname: Ferrante
authors.forename: B
authors.initials: B
authors.lastname: Vertogen
authors.forename: A
authors.initials: A
authors.lastname: Cariello
authors.forename: W
authors.initials: W
authors.lastname: Latino
authors.forename: F
authors.initials: F
authors.lastname: Zumaglini
authors.forename: M
authors.initials: M
authors.lastname: Marangolo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects; D007279:Injections, Subcutaneous; D008875:Middle Aged; D011446:Prospective Studies; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D016190:Carboplatin; D000069585:Filgrastim; D007069:Ifosfamide